[ad_1]
A Shanghai-based pharmaceutical company is seeking permission to market an innovative drug that treats mild to moderate Alzheimer's disease.
Called GV-971, the drug has completed its Phase 3 clinical trial and is According to a Green Valley press release, one of the co-developers of the drug, the first multi-targeting drug and to carbohydrate base for the treatment of AD in the world.
As Alzheimer's disease is characterized by the aggregation of amyloid β peptide, current research on possible treatments focuses primarily on the development of monoclonal antibodies that typically target limited sites of the species Aβ
. However, the GV971 offers a more holistic approach. The drug, which is an oligosaccharide extracted from brown algae, can bind to several Aβ regions and inhibit Aβ aggregation, the company said. Independent studies have also shown that GV-971 can remodel immune homeostasis, reduce neuroinflammation and improve cognitive impairment by repackaging dysbiosis of the gut microbiota
. Additionally, the drug does not showed no toxic side effects for 36 weeks. Double-blind, placebo-controlled clinical trial.
Green Valley said the company plans to submit the marketing authorization application to the China National Drug Administration later this year
. -971 was developed by the Shanghai Materia Medica Institute (SIMM) of the Chinese Academy of Sciences and the pharmaceutical company Green Valley. Insiders said the drug should drive a new wave of development of carbohydrate drugs.
Alzheimer's disease is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive function. According to Alzheimer's Disease International, there are approximately 48 million Alzheimer's disease patients in the world today, and this number is expected to reach 130 million by 2050 because of Alzheimer's disease. the rapid growth of the aging population.
[ad_2]
Source link
